Figure 1: SSAO inhibitors attenuate mechanical hyperalgesia and inflammatory signs in the K/BxN serum-transfer arthritis model.

Alterations of the (A) mechanonociceptive threshold, (B) paw volume, (C) semiquantitative clinical score, and (D) time spent on the grid in arthritic mice treated with the vehicle, SzV-1287 or LJP-1207 (20 mg/kg/day i.p. every day during the 13-day experimental period) as compared to the BxN serum-injected non-arthritic controls. Data are shown as means ± S.E.M. of n = 8–9 mice/group, *p < 0.05, **p < 0.01, ***p < 0.001 (vs. vehicle-treated arthritic mice), #p < 0.05, ###p < 0.001 (vs. vehicle-treated control mice); two-way ANOVA followed by Bonferroni’s multiple comparison test.